Cipla receives 4 nutrition brands from Wanbury
To begin with, homegrown pharma company, Cipla receives a nutrition product portfolio from Wanbury Ltd. So then, on Saturday, the company announced the acquisition of the products from the firm.
Besides, the 4 brands acquired include namely, CPink, CDense, Productiv, and also Folinine. Hence, this would further strengthen its presence in women’s health portfolio.
Despite this, the nutraceutical products that might remain sold under the 4 brands would address various health needs. Such as the conditions that arise due to nutritional deficiencies or insufficiencies.
Furthermore, this includes supplements such as multivitamins, multimineral, and antioxidants for adolescent girls, pregnant, and also for lactating women. Also, for women going through menopause and for male and female reproductive health.
However, with this newly acquired portfolio, the company might stand serving a huge range of patients’ needs. Such as nutritional deficiencies, bone health, and sexual health.
Besides, these molecules have previously remained commercialized by Wanbury. So then, it earned a market size of Rs 3,100 crores in India with sales of Rs 59.6 crores.
The Sensex and Nifty traded with a bearish trend today, on 8th Feb. The Sensex trading with a loss of 164.18 points reached 41,141.85 with 0.40% down. Whereas Nifty trading with a loss of 39.60 points reached 12,098.35 with 0.33% down.
